Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation

被引：77

作者：

Cook, RC

Connors, JM

Gascoyne, RD

Fradet, G

Levy, RD

机构：

[1] Univ British Columbia, British Columbia Canc Agcy, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada

[2] Univ British Columbia, British Columbia Canc Agcy, Div Pathol, Vancouver, BC V5Z 4E6, Canada

[3] Univ British Columbia, Lung Transplant Program, Vancouver, BC V5Z 4E6, Canada

[4] Vancouver Gen Hosp, Vancouver, BC V5Z 4E6, Canada

来源：

LANCET | 1999年 / 354卷 / 9191期

关键词：

D O I：

10.1016/S0140-6736(99)02058-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Three patients with diffuse large B-cell type of post-transplant lymphoproliferative disease after lung transplantation were treated with rituximab, an anti-CD20 monoclonal antibody. Treatment resulted in two complete remissions and one nonresponse.

引用

页码：1698 / 1699

页数：2

共 5 条

[1] Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome [J].

Benkerrou, M ;

Jais, JP ;

Leblond, V ;

Durandy, A ;

Sutton, L ;

Bordigoni, P ;

Garnier, JL ;

Le Bidois, J ;

Le Deist, F ;

Blanche, S ;

Fischer, A .

BLOOD, 1998, 92 (09) :3137-3147

[2] Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders [J].

Faye, A ;

Van Den Abeele, T ;

Peuchmaur, M ;

MAthieu-Boue, A ;

Vilmer, E .

LANCET, 1998, 352 (9136) :1285-1285

[3]

MAGRATH IT, 1997, NONHODGKINS LYMPHOMA, P955

[4] Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin [J].

Senderowicz, AM ;

Vitetta, E ;

Headlee, D ;

Ghetie, V ;

Uhr, JW ;

Figg, WD ;

Lush, RM ;

StetlerStevenson, M ;

Kershaw, G ;

Kingma, DW ;

Jaffe, ES ;

Sausville, EA .

ANNALS OF INTERNAL MEDICINE, 1997, 126 (11) :882-885

[5]

STARZL TE, 1984, LANCET, V1, P583

← 1 →